FermaVir Pharmaceuticals, Inc. (OTCBB:FMVR), committed to the development of breakthrough antiviral and other drug therapies, announced that it will present an overview of its proprietary antiviral drug candidates and pre-clinical development programs at BIO 2006, one of the biotechnology industry's leading annual conferences.
Dr. Geoffrey Henson, FermaVir CEO, will discuss the Company's portfolio of drug candidates, including a novel antiviral compound designed to treat the potentially serious and debilitating viral condition known as shingles. Research data suggests that FermaVir's compound, known by its laboratory designation CF-1743, is believed to be 10,000 times more potent than currently approved drug treatments for shingles, a viral disease in the herpes family.
The BIO 2006 Annual International Convention is scheduled for April 9-12 in Chicago at the McCormick Place Convention Center. Representatives from leading biotechnology companies, as well as from government and research institutions, will be in attendance at the conference. Dr. Henson's BIO 2006 presentation is slated for April 11, at 11 am.
CF-1743 is among a portfolio of FermaVir's proprietary candidates planned for development to treat a family of viral diseases caused by herpes viruses. Among FermaVir's other lead drug candidates are powerful antiviral compounds with a new mechanism of action to treat Cytomegalovirus infections, another potentially debilitating condition caused by a member of the herpes family of viruses, which can cause blindness and frequently afflicts patients with compromised immune systems.
FermaVir's Board of Directors and company founders include recognized world authorities on viral diseases. They include Dr. Erik de Clercq, the inventor of the HIV/AIDS drug Viread(TM), and Dr. Richard Whitley, considered one of the world's leading authorities on herpes-related diseases.
"I am excited to discuss FermaVir's technology portfolio and progress in the development of these powerful new antiviral compounds," said Dr. Henson. "These are the lead candidates in our strategic plan to expand our pipeline of needed medical therapies."
The BIO 2006 conference is organized by the Biotechnology Industry Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. For more information on the BIO 2006 Annual International Convention, visit http://www.bio.org/events/2006.
About FermaVir Pharmaceuticals, Inc.
FermaVir Pharmaceuticals, Inc. is an emerging biotechnology company positioned for rapid growth by developing important antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. The Company's Intellectual Property portfolio includes a number of patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases. Among FermaVir's lead drug candidates is a breakthrough antiviral treatment that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster. FermaVir's proprietary compound is believed to be 10,000 times more potent than currently approved shingles drug treatments. FermaVir is also developing a compound that could provide the first improved effective treatment in years for Cytomegalovirus (CMV) infection, a currently incurable viral disease from the herpes family that can threaten eyesight as well as cause severe morbidity and mortality. For more investor-specific information about FermaVir, please visit http://www.trilogy-capital.com/tcp/fermavir. For detailed stock quote information, visit http://www.trilogy-capital.com/tcp/fermavir/quote.html. To view or download an Investor Fact Sheet about FermaVir, please visit http://www.trilogy-capital.com/tcp/fermavir/factsheet.html.